VCBeat Health Contact Us
Home Zelgen's $1.2B+ Deal with AbbVie — First-in-Class DLL3 Trispecific Antibody Launches Phase III

Zelgen's $1.2B+ Deal with AbbVie — First-in-Class DLL3 Trispecific Antibody Launches Phase III

May 20, 2026 11:30 CST Updated 16:15
Zelgen

Innovative Drug Research and Development, Manufacturer